Evaluation of Fas gene promoter polymorphism in cervical cancer patients

Dybikowska, Aleksandra; Sliwiński, W; Emerich, Janusz; Podhajska, Anna J.

doi:10.3892/ijmm.14.3.475

Cited by 13 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations occur in immune diseases [10,33] and only occasionally in tumors [4,5,21,37]; however, to our knowledge, they have never been reported in cervical carcinomas. Promoter-region SNPs are known to occur in various carcinomas such as esophageal and cervical carcinoma [7,9,20,41,43]. Lai et al [20] recently reported that the frequency of the Fas 670-A allele increased from high-grade squamous intraepithelial lesions to invasive carcinomas, being approximately twice as frequent in patients with invasive carcinoma than the general population; however, this finding has not been confirmed by other investigators [7,9,43].…”

Section: Introductionmentioning

confidence: 94%

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

et al. 2007

View full text Add to dashboard Cite

We studied whether Fas-receptor (Fas-R; CD95) expression, single-nucleotide polymorphisms (SNPs) in the Fas promoter region, and/or Fas-ligand (Fas-L) production could determine individual susceptibility to cervical cancer progression. The clinicopathologic features of 38 patients with cervical squamous carcinomas (22 stage I, 8 stage II, and 8 stage III+) were reviewed and related with: (a) Fas-R expression by immunohistochemistry; (b) Fas-R SNPs at -670 and -1377 locations by restriction fragment length polymorphism and DNA sequencing; and (c) Fas-L expression by immunohistochemistry. Overall and disease-free survival curves showed significant differences in relation to stage (p < 0.001). Fas-R was identified in 20 of 38 (52.6%) tumors without statistical differences in survival, stage, or Fas-L overproduction. Fas-R GG genotype was more common than expected in advanced tumors (p = 0.065). The Fas-R-1377A allele and AA genotype were unrelated with survival, stage, or Fas-R expression. Fas-L overproduction was detected in 20 of 38 (52.6%) tumors; it was more frequent in advanced-stage tumors and was inversely related to survival (p = 0.03) and decrease in host inflammatory response (p = 0.01). Fas-R expression by tumor cells seems unrelated to stage or lymphoid infiltrate. Tumor production of Fas-L may represent an attempt to destroy the host's lymphocytic reaction.

show abstract

Section: Introductionmentioning

confidence: 94%

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Previous studies, including the 10 studies that we included in the present meta-analysis, were conducted to estimate the incidence of cervical carcinogenesis in association with the FAS-670 polymorphism; however, a consensus was not reached (13,(23)(24)(25)(26)(27)(28)(29)(30)(31). Zhang et al (32) conducted a meta-analysis on FAS promoter polymorphisms and cancer risk, but failed to demonstrate a significant association with FAS-670 polymorphism.…”

Section: Fas-670 Gene Polymorphism and Cervical Carcinogenesis Risk: mentioning

confidence: 99%

“…In all the studies, the majority of the patients were recruited from hospitals by blood samples or tissue specimens. Six studies mentioned the mean age of the patients (13,23,24,27,29,30) and the remaining 4 studies did not (25,26,28,31). All the studies used polymerase chain reaction.…”

Section: Identification and Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis

Huang

Wang

2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. FAS is a cell surface receptor that plays an important role in the etiology of cancer. Previous studies on the association between FAS-670 polymorphism and cervical carcinogenesis failed to reach a consensus; therefore, this meta-analysis was conducted to estimate the association of FAS-670 polymorphism and the risk of cervical cancer. This meta-analysis included 10 studies on FAS-670 genotyping, including a total of 2,901 cases and 2,831 controls. The complete overdominant model was applied in our meta- 2 =23.5%, P heterogeneity =0.03), whereas for Caucasians, no significant association was observed between FAS-670 polymorphism and cervical carcinogenesis (4 comparisons, OR=0.96, 95% CI: 0.75-1.24, I 2 =45.9%, P heterogeneity =0.14).

show abstract

“…The impact of the 670A ‡G change in the FASR gene decreases FAS expression, thus, abolishing gamma interferon signal transduction, leading to decreased apoptotic activity (Pavlidou et al, 2016). The FasR 670A allele is more common in Caucasians (51%) compared with Africans (29.5%) (Dybikowska et al, 2004;Lai et al, 2003;Pinti et al, 2002).…”

Section: Fas Cell Death Receptormentioning

confidence: 99%

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Kuguyo

Tsikai

Thomford

et al. 2018

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Human papillomavirus (HPV) is an essential but not a sufficient cervical cancer etiological factor. Cancer promoters, such as host genetic mutations, significantly modulate therapeutic responses and susceptibility. In cervical cancer, of interest have been viral clearing genes and HPV oncoprotein targets, for which conflicting data have been reported among different populations. This expert analysis evaluates cervical cancer genetic susceptibility biomarkers studied in African populations. Notably, the past decade has seen Africa as a hotbed of biomarker and precision medicine innovations, thus potentially informing worldwide biomarker development strategies. We conducted a critical literature search in PubMed/MEDLINE, Google Scholar, and Scopus databases for case-control studies reporting on cervical cancer genetic polymorphisms among Africans. We found that seven African countries conducted cervical cancer molecular epidemiology studies in one of Casp8, p53, CCR2, FASL, HLA, IL10, TGF-beta, and TNF-alpha genes. This analysis reveals a remarkable gap in cervical cancer molecular epidemiology among Africans, whereas cervical cancer continues to disproportionately have an impact on African populations. Genome-wide association, whole exome-and whole-genome sequencing studies confirmed the contribution of candidate genes in cervical cancer. With such advances and omics technologies, the role of genetic susceptibility biomarkers can be exploited to develop novel interventions to improve current screening, diagnostic and prognostic methods worldwide. Exploring these genetic variations is crucial because African populations are genetically diverse and some variants or their combined effects are yet to be discovered and translated into tangible clinical applications. Thus, translational medicine and flourishing system sciences in Africa warrant further emphasis in the coming decade.

show abstract

Evaluation of Fas gene promoter polymorphism in cervical cancer patients

Cited by 13 publications

References 0 publications

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Contact Info

Product

Resources

About